Symbols / BDRX
BDRX Chart
About
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.03M |
| Enterprise Value | 79.91B | Income | -6.23M | Sales | — |
| Book/sh | 25.15 | Cash/sh | 4036000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.05 | P/C | — |
| EV/EBITDA | -9007.54 | EV/Sales | — | Quick Ratio | 3.63 |
| Current Ratio | 3.63 | Debt/Eq | 4.38 | LT Debt/Eq | — |
| EPS (ttm) | -27.23 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2020-09-09 20:00 | ROA | -39.04% |
| ROE | -61.77% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 838.79K |
| Shs Float | 45.37B | Short Float | 7.31% | Short Ratio | 0.20 |
| Short Interest | — | 52W High | 47.00 | 52W Low | 1.04 |
| Beta | 0.99 | Avg Volume | 1.16M | Volume | 94.26K |
| Target Price | — | Recom | None | Prev Close | $1.29 |
| Price | $1.23 | Change | -4.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.23
Latest analyst target
3. DCF / Fair value
$-201.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.23
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-02-08 | init | Ladenburg Thalmann | — → Buy | $8 |
- 12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga ue, 17 Feb 2026 17
- Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Wed, 03 Sep 2025 07
- Biodexa adds 'molecular glue' treatment for GIST tumours in Otsuka deal - Stock Titan Wed, 04 Feb 2026 08
- Biodexa Pharmaceuticals stock falls after $10 million public offering - Investing.com hu, 18 Dec 2025 08
- 12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga ue, 17 Feb 2026 21
- Biodexa Pharmaceuticals’ Soaring Stock: Time to Decide? - timothysykes.com Mon, 15 Dec 2025 08
- Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold - TechStock² Wed, 10 Dec 2025 08
- Biodexa Pharmaceuticals PLC Announces $10 Million Public Offering Pricing - Quiver Quantitative hu, 18 Dec 2025 08
- Biodexa Pharmaceuticals: Stock Rise Explained - StocksToTrade ue, 16 Dec 2025 08
- Biodexa (Nasdaq: BDRX) opens European arm of pivotal Phase 3 Serenta FAP trial - Stock Titan Mon, 01 Dec 2025 08
- Surging Stocks: AMCI, BDRX, SURG, VMAR, TOON More Stocks Inside - FinancialContent Wed, 17 Dec 2025 08
- Is BDRX’s ROE strong enough - July 2025 Analyst Calls & Real-Time Volume Analysis Alerts - mfd.ru Fri, 13 Feb 2026 17
- Biodexa Pharmaceuticals Stock Surges: What’s Next? - timothysykes.com Wed, 10 Dec 2025 08
- Biodexa Stock Surges: What’s Next for Investors? - StocksToTrade Wed, 10 Dec 2025 08
- BDRX Stock Price, News & Analysis | Biodexa Pharmaceuticals - Stock Titan Fri, 25 Apr 2025 00
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 134.55K | 26.42K | 45.87K | 99.03K |
| TaxRateForCalcs | 0.04 | 0.05 | 0.10 | 0.11 |
| NormalizedEBITDA | -8.78M | -7.65M | -8.56M | -6.59M |
| TotalUnusualItems | 3.22M | 487.00K | 468.00K | 936.00K |
| TotalUnusualItemsExcludingGoodwill | 3.22M | 487.00K | 468.00K | 936.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.73M | -7.08M | -7.66M | -5.46M |
| ReconciledDepreciation | 254.00K | 283.00K | 343.00K | 403.00K |
| ReconciledCostOfRevenue | 5.44M | 4.07M | 5.11M | 4.65M |
| EBITDA | -5.56M | -7.16M | -8.09M | -5.66M |
| EBIT | -5.81M | -7.44M | -8.44M | -6.06M |
| NetInterestIncome | 2.00K | 42.00K | -24.00K | -44.00K |
| InterestExpense | 165.00K | 41.00K | 53.00K | 44.00K |
| InterestIncome | 167.00K | 83.00K | 29.00K | 0.00 |
| NormalizedIncome | -8.81M | -7.54M | -8.08M | -6.30M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.73M | -7.08M | -7.66M | -5.46M |
| TotalExpenses | 9.20M | 8.39M | 9.63M | 7.58M |
| TotalOperatingIncomeAsReported | -9.20M | -8.01M | -8.93M | -7.00M |
| DilutedAverageShares | 49.53K | 3.16K | 12.35K | 10.07K |
| BasicAverageShares | 49.53K | 3.16K | 12.35K | 10.07K |
| DilutedEPS | -100.00 | -2.00K | -155.00K | -140.00K |
| BasicEPS | -100.00 | -2.00K | -155.00K | -140.00K |
| DilutedNIAvailtoComStockholders | -5.73M | -7.08M | -7.66M | -5.46M |
| NetIncomeCommonStockholders | -5.73M | -7.08M | -7.66M | -5.46M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | ||
| NetIncome | -5.73M | -7.08M | -7.66M | -5.46M |
| NetIncomeIncludingNoncontrollingInterests | -5.73M | -7.08M | -7.66M | -5.46M |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | -5.73M | -7.08M | -7.66M | -5.46M |
| TaxProvision | -250.00K | -406.00K | -832.00K | -646.00K |
| PretaxIncome | -5.98M | -7.49M | -8.49M | -6.11M |
| OtherIncomeExpense | 3.22M | 487.00K | 468.00K | 936.00K |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | 3.22M | 487.00K | 468.00K | 936.00K |
| NetNonOperatingInterestIncomeExpense | 2.00K | 42.00K | -24.00K | -44.00K |
| InterestExpenseNonOperating | 165.00K | 41.00K | 53.00K | 44.00K |
| InterestIncomeNonOperating | 167.00K | 83.00K | 29.00K | 0.00 |
| OperatingIncome | -9.20M | -8.01M | -8.93M | -7.00M |
| OperatingExpense | 3.76M | 4.33M | 4.52M | 2.92M |
| OtherOperatingExpenses | -31.00K | -14.00K | -22.00K | -24.00K |
| SellingGeneralAndAdministration | 3.79M | 4.34M | 4.54M | 2.95M |
| SellingAndMarketingExpense | 0.00 | |||
| GeneralAndAdministrativeExpense | 3.79M | 4.34M | 4.54M | 2.95M |
| OtherGandA | 3.79M | 4.34M | 4.54M | 2.95M |
| GrossProfit | -5.44M | -3.69M | -4.41M | -4.08M |
| CostOfRevenue | 5.44M | 4.07M | 5.11M | 4.65M |
| TotalRevenue | 0.00 | 381.00K | 699.00K | 578.00K |
| OperatingRevenue | 0.00 | 381.00K | 699.00K | 578.00K |
| Line Item | 2022-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 6.69B | 1.19B | 5.42M | 4.92M |
| ShareIssued | 6.69B | 1.19B | 5.42M | 4.92M |
| TotalDebt | 727.00K | 464.00K | 624.00K | 766.00K |
| TangibleBookValue | 2.68M | 1.74M | 3.16M | 10.45M |
| InvestedCapital | 8.32M | 4.68M | 3.16M | 10.45M |
| WorkingCapital | 3.78M | 1.46M | 2.79M | 9.92M |
| NetTangibleAssets | 2.68M | 1.74M | 3.16M | 10.45M |
| CapitalLeaseObligations | 727.00K | 464.00K | 624.00K | 766.00K |
| CommonStockEquity | 8.32M | 4.68M | 3.16M | 10.45M |
| TotalCapitalization | 8.32M | 4.68M | 3.16M | 10.45M |
| TotalEquityGrossMinorityInterest | 8.32M | 4.68M | 3.16M | 10.45M |
| StockholdersEquity | 8.32M | 4.68M | 3.16M | 10.45M |
| OtherEquityInterest | 5.93M | 8.52M | 1.72M | 1.72M |
| GainsLossesNotAffectingRetainedEarnings | 53.00M | 53.00M | 53.00M | 53.00M |
| OtherEquityAdjustments | 53.00M | 53.00M | 53.00M | 53.00M |
| ForeignCurrencyTranslationAdjustments | 0.00 | 0.00 | ||
| RetainedEarnings | -150.42M | -144.77M | -135.34M | -127.80M |
| AdditionalPaidInCapital | 93.12M | 86.73M | 83.67M | 83.43M |
| CapitalStock | 6.69M | 1.19M | 108.34K | 98.47K |
| CommonStock | 6.69M | 1.19M | 108.34K | 98.47K |
| TotalLiabilitiesNetMinorityInterest | 6.46M | 5.86M | 2.36M | 2.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.42M | 295.00K | 462.66K | 619.53K |
| OtherNonCurrentLiabilities | 1.31M | -344.00 | -469.00 | |
| LongTermDebtAndCapitalLeaseObligation | 118.00K | 295.00K | 463.00K | 620.00K |
| LongTermCapitalLeaseObligation | 118.00K | 295.00K | 463.00K | 620.00K |
| LongTermDebt | 0.00 | |||
| CurrentLiabilities | 5.03M | 5.57M | 1.90M | 1.84M |
| OtherCurrentLiabilities | 921.00K | 4.16M | 85.00K | 553.00K |
| CurrentDeferredLiabilities | 1.47M | 0.00 | 197.00K | 0.00 |
| CurrentDeferredRevenue | 1.47M | 0.00 | 197.00K | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 609.00K | 169.00K | 161.00K | 146.00K |
| CurrentCapitalLeaseObligation | 609.00K | 169.00K | 161.00K | 146.00K |
| CurrentDebt | 0.00 | 0.00 | ||
| CurrentProvisions | 207.00K | 50.00K | ||
| PayablesAndAccruedExpenses | 2.04M | 1.24M | 1.25M | 1.09M |
| CurrentAccruedExpenses | 1.27M | 857.00K | 817.00K | 546.00K |
| Payables | 763.00K | 383.00K | 433.00K | 546.00K |
| OtherPayable | 6.00K | 7.00K | 17.00K | 5.00K |
| TotalTaxPayable | 50.00K | 62.00K | 77.00K | 56.00K |
| AccountsPayable | 707.00K | 314.00K | 339.00K | 485.00K |
| TotalAssets | 14.78M | 10.54M | 5.53M | 12.91M |
| TotalNonCurrentAssets | 5.97M | 3.51M | 837.00K | 1.15M |
| GoodwillAndOtherIntangibleAssets | 5.65M | 2.94M | 6.00K | 0.00 |
| OtherIntangibleAssets | 5.65M | 2.94M | 6.00K | |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 |
| NetPPE | 324.00K | 571.00K | 831.00K | 1.15M |
| AccumulatedDepreciation | -1.22M | -1.73M | -1.63M | -1.64M |
| GrossPPE | 1.54M | 2.30M | 2.46M | 2.79M |
| Leases | 53.00K | 53.00K | 53.00K | 53.00K |
| OtherProperties | 1.40M | 2.13M | 2.26M | 2.44M |
| MachineryFurnitureEquipment | 88.00K | 113.00K | 151.00K | 302.00K |
| BuildingsAndImprovements | 53.00K | 53.00K | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.81M | 7.03M | 4.69M | 11.76M |
| PrepaidAssets | 6.43M | 355.00K | 376.00K | 607.00K |
| Receivables | 715.00K | 704.00K | 1.48M | 1.10M |
| OtherReceivables | 131.00K | 282.00K | 301.00K | 394.00K |
| TaxesReceivable | 573.00K | 422.00K | 846.00K | 670.00K |
| AccountsReceivable | 11.00K | 0.00 | 329.00K | 33.00K |
| CashCashEquivalentsAndShortTermInvestments | 1.67M | 5.97M | 2.84M | 10.06M |
| CashAndCashEquivalents | 1.67M | 5.97M | 2.84M | 10.06M |
| CashFinancial | 1.67M | 5.97M | 2.84M | 10.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.04M | -7.09M | -7.11M | -6.33M |
| RepaymentOfDebt | -186.00K | -188.00K | -178.00K | -215.00K |
| IssuanceOfDebt | 431.00K | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 8.31M | 10.43M | 243.00K | 9.04M |
| CapitalExpenditure | -774.00K | -263.00K | -62.00K | -320.00K |
| EndCashPosition | 1.67M | 5.97M | 2.84M | 10.06M |
| BeginningCashPosition | 5.97M | 2.84M | 10.06M | 7.55M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | 0.00 | -8.00K |
| ChangesInCash | -4.30M | 3.13M | -7.22M | 2.52M |
| FinancingCashFlow | 8.56M | 10.23M | 47.00K | 8.80M |
| CashFlowFromContinuingFinancingActivities | 8.56M | 10.23M | 47.00K | 8.80M |
| InterestPaidCFF | 0.00 | -13.00K | -18.00K | -15.00K |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 8.31M | 10.43M | 243.00K | 9.04M |
| CommonStockIssuance | 8.31M | 10.43M | 243.00K | 9.04M |
| NetIssuancePaymentsOfDebt | 245.00K | -188.00K | -178.00K | -215.00K |
| NetShortTermDebtIssuance | 431.00K | 0.00 | 0.00 | |
| ShortTermDebtIssuance | 431.00K | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -186.00K | -188.00K | -178.00K | -215.00K |
| LongTermDebtPayments | -186.00K | -188.00K | -178.00K | -215.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -598.00K | -265.00K | -220.00K | -278.00K |
| CashFlowFromContinuingInvestingActivities | -598.00K | -265.00K | -220.00K | -278.00K |
| NetOtherInvestingChanges | -79.00K | -207.00K | ||
| InterestReceivedCFI | 176.00K | 73.00K | 29.00K | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -765.00K | -237.00K | 0.00 | 0.00 |
| PurchaseOfIntangibles | -765.00K | -237.00K | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -9.00K | -22.00K | -42.00K | -278.00K |
| SaleOfPPE | 0.00 | 4.00K | 20.00K | 42.00K |
| PurchaseOfPPE | -9.00K | -26.00K | -62.00K | -320.00K |
| OperatingCashFlow | -12.26M | -6.83M | -7.05M | -6.01M |
| CashFlowFromContinuingOperatingActivities | -12.26M | -6.83M | -7.05M | -6.01M |
| TaxesRefundPaid | 129.00K | 845.00K | 678.00K | 1.16M |
| ChangeInWorkingCapital | -3.74M | -49.00K | 520.00K | -617.00K |
| ChangeInOtherWorkingCapital | -207.00K | 157.00K | ||
| ChangeInPayablesAndAccruedExpense | 2.24M | -207.00K | 356.00K | -130.00K |
| ChangeInPayable | 2.24M | -207.00K | 356.00K | -130.00K |
| ChangeInReceivables | -5.97M | 365.00K | 7.00K | -487.00K |
| OtherNonCashItems | -2.00K | -42.00K | 24.00K | 44.00K |
| StockBasedCompensation | 283.00K | 28.00K | 123.00K | 89.00K |
| AssetImpairmentCharge | 0.00 | 79.00K | 207.00K | 0.00 |
| DeferredTax | -250.00K | -406.00K | -832.00K | -646.00K |
| DeferredIncomeTax | -250.00K | -406.00K | -832.00K | -646.00K |
| DepreciationAmortizationDepletion | 254.00K | 283.00K | 343.00K | 403.00K |
| DepreciationAndAmortization | 254.00K | 283.00K | 343.00K | 403.00K |
| AmortizationCashFlow | 2.00K | 3.00K | 3.00K | 0.00 |
| AmortizationOfIntangibles | 2.00K | 3.00K | 3.00K | 0.00 |
| Depreciation | 252.00K | 280.00K | 340.00K | 403.00K |
| OperatingGainsLosses | -3.21M | -485.00K | -455.00K | -978.00K |
| GainLossOnInvestmentSecurities | -3.22M | -487.00K | -468.00K | -936.00K |
| NetForeignCurrencyExchangeGainLoss | 4.00K | 0.00 | -1.00K | -3.00K |
| GainLossOnSaleOfPPE | 4.00K | 2.00K | 14.00K | -39.00K |
| NetIncomeFromContinuingOperations | -5.73M | -7.08M | -7.66M | -5.46M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BDRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|